{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '4.', 'OBJECTIVES AND ENDPOINTS', 'Objectives', 'Endpoints', 'Primary', 'To assess whether danirixin HBr', 'Rate of decline in FEV1', '35mg tablets impacts disease', \"Change from baseline in St. George's\", 'progression compared with placebo', 'Respiratory Questionnaire (SGRQ)', 'total score (derived from SGRQ-C)', 'Secondary', 'To further characterize the safety of', 'Adverse events (AE), clinical', 'danirixin HBr 35mg tablets compared', 'laboratory values, vital signs,', 'with placebo in participants with mild', 'electrocardiogram (ECG), and/or other', 'to moderate airflow limitation', 'safety biomarkers', 'To further characterize the clinical', 'Time to first HCRU COPD', 'activity of danirixin HBr 35mg tablets', 'exacerbation', 'compared to placebo', 'Change from baseline in FEV1', 'SGRQ responder analysis', 'SGRQ domains', 'COPD Assessment Test (CAT)', 'Rescue medication use', 'Exploratory', 'To characterize the effect of', 'Blood/serum/plasma biomarkers that', 'danirixin on lung matrix', 'are indicative of extracellular matrix', 'destruction/remodelling and', 'turnover/remodelling (e.g. elastin and', 'inflammation', 'collagen neo-epitopes) and', 'inflammation (e.g. CRP)', 'Further characterize efficacy of', 'danirixin', 'Global assessment of COPD severity', '22']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.', 'STUDY DESIGN', '5.1.', 'Overall Design', 'A study schematic is shown in Figure 1. This is a parallel group study. Following', 'screening and assessment of rescue medication use via a daily diary over study days - -32', 'to 1, participants will be randomized (1:1) to receive either danirixin 35mg tablets or', 'placebo. Study treatment will be administered twice daily for 52 weeks [Figure 1].', 'There will be no pre-specified interim analysis for this study. An interim analysis may be', 'performed if it is determined that the enrolment is slow enough to allow it to be', 'informative. There will be no IDMC for this study. An internal safety review team will', 'meet approximately every 3 months (or as needed based on emerging data) to review', 'available safety information.', 'Figure 1', 'Study Schematic', 'Up to', '52 weeks', '32 days', 'Placebo (n=50)', 'R', '1', 'Screening', 'Follow-up 2', 'Danirixin, 35mg', '(n=50)', '1', 'If changes to medication are required, consent must be signed prior to any', 'changes being made and may occur prior to the Screening Visit', '2', 'Follow-up visit to occur within 28days of last dose of study medication', '5.2.', 'Number of Participants', 'Approximately 130 participants will be screened to achieve 100 randomized in this study.', 'It', 'is anticipated that approximately 85 participants will complete the 12 months of', 'treatment (assuming a 15% drop out rate).', 'For the analysis of study assessments, several analysis populations are defined in Section', '10.3.', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'planned study visits including the last study visit and the last scheduled procedure shown', 'in the Schedule of Activities (Table 1).', 'The end of the study is defined as the date of the last visit of the last participant in the', 'study.', '23']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '5.4.', 'Scientific Rationale for Study Design', 'This study will use a multicenter, randomized, parallel-group design. This is a well', 'established design to evaluate the efficacy and safety of an investigational drug. With the', 'use of an enriched population, it is anticipated that one year of treatment will be sufficient', 'to detect a trend in altering disease progression. Danirixin has already been clinically', 'investigated over one year treatment duration (GlaxoSmithKline Document Number', '2013N180289_03 Study ID 200163).', 'The data from this study will provide useful information in determining whether or not to', 'progress to a Phase III study to explore an indication for slowing disease progression.', '5.5.', 'Dose Justification', 'One dose of danirixin is proposed for this study, 35mg tablets BID. This dose was', 'selected based on integrating information on:', 'Dose-exposure-biomarker response using inhibition of ex vivo CXCL1-induced', 'CD11b expression on peripheral blood neutrophils over the dose range of 0-400mg', '(free base tablet) in healthy volunteers (GSK Study No. CX3 112483).', 'Evidence of reduced respiratory symptoms and improvement in health status in mild', 'to moderate COPD participants from interim data in the Phase IIa study (GSK Study', 'No. 200163).', 'Relative bioavailability study comparing danirixin free base VS HBr (GSK Study No.', '201037).', 'In the previous clinical studies, danirixin was administered as a free base tablet, whereas', 'the danirixin formulation to be used in this study will be a hydrobromide salt tablet.', 'The hydrobromide tablet has approximately twice the bioavailability of the free base', 'tablet in healthy elderly participants (GlaxoSmithKline Document Number', '2015N248339 00, Study ID 201037). Thus the danirixin (hydrobromide tablet) 35mg', 'BID dose for investigation in this study is expected to provide steady-state systemic', 'exposure approximately equivalent to the 75mg BID (free base tablet) used in Study', '200163. Predicted steady-state exposures and multiples of blood ex vivo CXCL1-induced', 'CD11b pharmacology at the proposed danirixin doses are presented in Table 2.', 'Table 2', 'Predicted steady state systemic exposure and multiples of blood ex', 'vivo CXCL1-induced pharmacology following twice daily of', 'administration of danirixin', 'Dose', 'Predicted# steady-state median (5th, 95th', 'Cavg', 'Cmin', '(mg)', 'percentile)', 'multiple of', 'multiple of', 'AUC(0-24)', 'Cavg', 'Cmin', 'IC50*', 'IC50*', 'steady-state', '(ng/mL)', '(ng/mL)', '(ug.h/mL)', '35', '9.59', '399', '192', '5.1', '2.4', '(4.70, 19.3)', '(196, 806)', '(47.6,630)', '24']\n\n###\n\n", "completion": "END"}